Barrow, Hanley, Mewhinney & Strauss
CBPO

Barrow, Hanley, Mewhinney & Strauss’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-700
Closed -$57K – 457
2018
Q1 		$57K Buy
+700
New +$56.6K ﹤0.01% 356

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's CBPO Position: Q2 2018 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2018, closing a stake of 700 shares — an estimated $57K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in CBPO in Q1 2018 and held it in 1 quarter. The position peaked at $57K in Q1 2018. 91 funds tracked by Wall St. Rank hold CBPO as of Q2 2018.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2018 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 700 China Biologic Products Holdings, Inc. shares in Q2 2018, an estimated $57K.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in China Biologic Products Holdings, Inc. in Q1 2018 and held it in 1 quarter.
  • Barrow, Hanley, Mewhinney & Strauss's China Biologic Products Holdings, Inc. position peaked at $57K in Q1 2018.
  • 91 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2018.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2018, filed 14 Aug 2018.